Related Experiment Video
Updated: Nov 18, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.7K
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial
Douglas L Packer1, Jonathan P Piccini2, Kristi H Monahan1
1Mayo Clinic Hospital, St. Marys Campus, Rochester, MN (D.L.P., K.H.M., P.A.N.).
Circulation
|February 8, 2021
Summary
Catheter ablation significantly improved survival and reduced atrial fibrillation recurrence in heart failure patients compared to drug therapy. Quality of life also saw important gains with ablation treatment.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Atrial fibrillation (AF) and heart failure (HF) often coexist, impacting patient outcomes.
- Catheter ablation has shown promise in improving clinical outcomes for patients with AF and HF.
Purpose of the Study:
- To evaluate treatment-related outcomes of catheter ablation versus antiarrhythmic drug therapy in patients with AF and heart failure within the CABANA trial.
- To assess the impact of ablation on primary composite endpoints, mortality, AF recurrence, and quality of life.
Main Methods:
- Randomized 2204 patients with AF to either catheter ablation or drug therapy.
- Focused analysis on 778 patients with New York Heart Association class >II heart failure at baseline.
- Primary endpoint was a composite of death, disabling stroke, serious bleeding, or cardiac arrest.
Main Results:
- Catheter ablation demonstrated a 36% relative reduction in the primary composite endpoint and a 43% reduction in all-cause mortality compared to drug therapy.
- AF recurrence was significantly decreased in the ablation arm (HR, 0.56).
- Quality of life scores (AFEQT, MAFSI) significantly favored catheter ablation.
Conclusions:
- Catheter ablation offers clinically important improvements in survival, AF recurrence, and quality of life for stable heart failure patients with AF.
- These findings, observed in a cohort with predominantly preserved left ventricular function, warrant further independent verification.
- The CABANA trial provides key data on ablation's efficacy in this complex patient population.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
667
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
667
01:30Heart Failure V: Medical Management
89
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
89
01:22Heart Failure Drugs: β-Blockers
557
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
557
01:22Heart Failure VI: Adjunct Therapies
107
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
107
01:22Heart Failure Drugs: Diuretics
611
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
611
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K